• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $218.70 In stock
10 mg $337.40 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2

Purity

≥98%

Formula

C27H20ClFN4O4

Formula Wt.

518.92

IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid

Synonym

Alisertib

Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble

Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF

Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C0170

    N-(4-Carbethoxyphenyl)retinamide

    Retinoid, differentiation inducer.

    ≥98%
  • R5878

    Rotenone

    Micronuclei formation inducer, antimitotic, oxi...

    ≥97%
  • G0244

    alpha-Galactosylceramide

    Synthetic glycolipid found in Agelas mauritaniu...

    ≥96%
  • E5240

    Leu-Enkephalin

    Endogenous opioid peptide; δOR and μOR agonis...

    ≥95%
  • P1854

    Penicillic Acid

    Neuroactive mycotoxin produced by Penicillum an...

    ≥98%
  • C4658

    Clopidogrel Sulfate

    Thienopyridine; P2Y12 antagonist.

    ≥98%
  • A4849

    Amyloid-β (25-35)

    Endogenous APP peptide cleavage product, primar...

    ≥95%
  • H014458

    Halometasone

    Glucocorticoid

    ≥98%
  • M1976

    Methimazole

    Thioamide; thyroid peroxidase inhibitor.

    ≥98%
  • U6901

    Uracil

    Endogenous pyrimidine base required for product...

    ≥98%
  • B5875

    Bosutinib, structural isomer

    Bosutinib isomer; Src and Abl inhibitor.

    ≥98%
  • D5794

    Doxorubicin Hydrochloride

    Anthracycline, DNA intercalator; topoisomerase II ...
    ≥98%
  • W9602

    WY-14643

    A peroxisome proliferator-activated receptor ag...

    ≥98%
  • H9613

    N-(4-Hydroxyphenyl)retinamide

    Retinol (vitamin A) analog, binds RBP4; Des1 in...

    ≥98%
  • T2932

    Thiamphenicol Glycinate Hydrochloride

    Chloramphenicol derivative; protein translation...

    ≥98%
  • I5215

    Indolicidin

    Antimicrobial peptide.

    ≥95%
  • J3204

    E-JIB-04

    Jumonji histone demethylase inhibitor.

    ≥98%
  • I0801

    IC261

    Casein kinase 1 inhibitor.

    ≥98%
  • E537331

    Enniatin Complex

    Mycotoxin contaminant found in cereal grains.

    ≥98%
  • C691325

    Cridanimod

    STING agonist

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only